Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Impact of early analgesia on hospitalization outcomes for sickle cell pain crisisMedical and Pediatric Oncology.  65. 2018
2018 Red blood cell transfusion therapy for sickle cell patients with frequent painful eventsMedical and Pediatric Oncology.  65. 2018
2018 Outcomes in mild to moderate isolated thrombocytopeniaPediatrics.  142. 2018
2016 A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosisJournal of Immunology.  196:2492-2503. 2016
2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemiaJournal of Blood Medicine.  6:285-290. 2015
2015 Health-related quality of life in infants with sickle cell diseaseJournal of Pediatric Hematology/Oncology.  37:590-594. 2015
2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell diseaseJournal of Neurosurgery: Pediatrics.  16:64-73. 2015
2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.International journal of hematology & therapy.  1. 2015
2015 Patient-centered approach to designing sickle cell transition educationJournal of Pediatric Hematology/Oncology.  37:43-47. 2015
2014 PedsQL™ multidimensional fatigue scale in sickle cell disease: Feasibility, reliability, and validityMedical and Pediatric Oncology.  61:171-177. 2014
2013 PedsQL™ sickle cell disease module: Feasibility, reliability, and validityMedical and Pediatric Oncology.  60:1338-1344. 2013
2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia.Journal of Blood Medicine.  3:105-112. 2012
2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
2010 Single institution series of nodular fasciitis in childrenJournal of Pediatric Hematology/Oncology.  32:354-357. 2010

Investigator On

  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT Trial)  awarded by ALL CHILDREN'S RESEARCH INSTITUTE 2018 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • Private Grant  awarded by SANCILIO & COMPANY, INC. 2017 - 2020
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT Trial)  awarded by ALL CHILDREN'S RESEARCH INSTITUTE 2017 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • The Kids - DOTT Trial  awarded by ALL CHILDREN'S RESEARCH INSTITUTE 2015 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • Private Grant  awarded by TERUMO BCT, INC. 2012 - 2013
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2006
  • Bachelor's Degree in Political Science and Government, University of Alabama at Birmingham 2001
  • UAB Hospital, Internship 2007
  • UAB Hospital, Residency 2009
  • UAB Hospital, Postdoctoral Fellowship 2012
  • Full Name

  • Christina Bemrich-Stolz